Search Results

Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.

Following completion of the Sale of Assets to KemPharm, Orphazyme will no longer have any material ongoing operational business activities and KemPharm will retain all of Orphazyme’s remaining Danish employees, to continue the early access programs with arimoclomol, and to continue to pursue the potential approval of arimoclomol as a treatment option for NPC.

Orphazyme has several products with potential, with biopharma company KemPharm acquiring nearly all of the company’s assets and operations.

Orphazyme A/S, a late-stage biopharmaceutical company, announces that CFO Anders Vadsholt will be appointed CEO of Orphazyme effective as of March 1, 2022 and thereby replacing Christophe Bourdon as announced in company announcement no. 3/2022 of January 31, 2022.

The Orphazyme board of directors decided to cut 50% of its current global staff count after carefully considering its financial state.

Orphazyme A/S Company today announces that Chief Executive Officer (CEO) Christophe Bourdon will resign from his position as CEO at Orphazyme.

Orphazyme A/S, reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.

Orphazyme A/S today announces an update to its financial outlook for 2021 based on a review of preliminary unaudited financial results for the year ending December 31, 2021.

Orphazyme A/S announces that following the Company’s filing of a petition for an in-court restructuring (in Danish rekonstruktion) of Orphazyme on March 10, 2022, the Danish Maritime and Commercial High Court (the “Court”) has commenced the restructuring proceedings of the Company on March 11, 2022 at 7:00 am (CET).

Orphazyme A/S, today initiated the delisting and filed a Form 25 with the Securities and Exchange Commission (“SEC”). The delisting is expected to become effective on March 31, 2022.